JP2015515462A5 - - Google Patents

Download PDF

Info

Publication number
JP2015515462A5
JP2015515462A5 JP2015501731A JP2015501731A JP2015515462A5 JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5 JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5
Authority
JP
Japan
Prior art keywords
blood
pegylated
composition
subject
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015501731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515462A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/030355 external-priority patent/WO2013142135A1/en
Publication of JP2015515462A publication Critical patent/JP2015515462A/ja
Publication of JP2015515462A5 publication Critical patent/JP2015515462A5/ja
Pending legal-status Critical Current

Links

JP2015501731A 2012-03-20 2013-03-12 輸血の有効性を高める方法 Pending JP2015515462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613105P 2012-03-20 2012-03-20
US61/613,105 2012-03-20
PCT/US2013/030355 WO2013142135A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Publications (2)

Publication Number Publication Date
JP2015515462A JP2015515462A (ja) 2015-05-28
JP2015515462A5 true JP2015515462A5 (https=) 2016-04-21

Family

ID=49223191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501731A Pending JP2015515462A (ja) 2012-03-20 2013-03-12 輸血の有効性を高める方法

Country Status (10)

Country Link
US (2) US8859499B2 (https=)
EP (1) EP2827887A4 (https=)
JP (1) JP2015515462A (https=)
BR (1) BR112014023200A2 (https=)
CL (1) CL2014002464A1 (https=)
HK (1) HK1204267A1 (https=)
IN (1) IN2014MN02089A (https=)
MX (1) MX2014011186A (https=)
WO (1) WO2013142135A1 (https=)
ZA (1) ZA201407616B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP2827887A4 (en) 2012-03-20 2016-04-20 Einstein Coll Med METHOD FOR IMPROVING THE EFFECTIVENESS OF BLOOD TRANSFUSIONS
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
MX2016007492A (es) * 2013-12-09 2017-03-06 Univ Leland Stanford Junior Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
WO2016077825A1 (en) * 2014-11-14 2016-05-19 Aima Biotech Conjugated proteins
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3096160B1 (en) * 2015-05-20 2020-02-26 Veoneer Sweden AB An fmcw vehicle radar system
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
KR20240025721A (ko) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
WO2017083281A1 (en) * 2015-11-09 2017-05-18 Albert Einstein College Of Medicine, Inc. Method of ameliorating side effects of sickle cell disease treatments
WO2017103914A1 (en) 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
ES2900302T3 (es) 2016-04-28 2022-03-16 Alkahest Inc Fracciones de plasma como terapia para el crecimiento y la progresión del tumor
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2018200560A1 (en) 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
US11504417B2 (en) 2017-07-18 2022-11-22 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
CN119345230A (zh) 2018-10-26 2025-01-24 万能溶剂有限公司 血浆和血浆组分用于改善疼痛的用途
JP7773169B2 (ja) * 2021-02-24 2025-11-19 学校法人 中央大学 ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
JPS56139419A (en) * 1980-03-31 1981-10-30 Kuraray Co Ltd Erythrocytic preservative and erythrocytic pharmaceutical for preservation
US6129912A (en) * 1997-09-26 2000-10-10 Uab Research Foundation Polyethylene glycol-protein compositions which reduce the antigenic display of red blood cells
ATE256474T1 (de) * 1998-09-25 2004-01-15 Oklahoma Med Res Found Hemmung der sichelbildung von erythrozyten mittels n-l-alpha-aspartyl-l-phenylalanine 1- methylester
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US6875423B1 (en) * 1999-09-21 2005-04-05 Marcos Intaglietta Methods for increasing peripheral blood circulation
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
US6811778B2 (en) 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
AU2005311251A1 (en) * 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
US8071546B2 (en) * 2005-06-10 2011-12-06 La Jolla Bioengineering Institute Uses of pegylated albumin
CN102300555B (zh) * 2009-01-30 2015-06-17 卡斯伯特·O·辛普金斯 复苏液
US8815297B2 (en) * 2009-03-31 2014-08-26 Duke University Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
KR102170375B1 (ko) * 2009-06-09 2020-10-27 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
US20130231287A1 (en) * 2010-02-25 2013-09-05 Parimala Nacharaju Pegylated albumin polymers and uses thereof
EP2827887A4 (en) 2012-03-20 2016-04-20 Einstein Coll Med METHOD FOR IMPROVING THE EFFECTIVENESS OF BLOOD TRANSFUSIONS
WO2016077825A1 (en) 2014-11-14 2016-05-19 Aima Biotech Conjugated proteins

Similar Documents

Publication Publication Date Title
JP2015515462A5 (https=)
Li et al. Scaffold-facilitated locomotor improvement post complete spinal cord injury: Motor axon regeneration versus endogenous neuronal relay formation
JP2014520142A5 (https=)
JP2011088927A5 (https=)
NZ592837A (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CN102406205B (zh) 牡蛎多糖果汁饮料
JP2017505761A5 (https=)
JP2017532343A5 (https=)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
MX387845B (es) Polímeros enlazados al proton para administracion oral.
JP2012528890A5 (https=)
Lieder et al. Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes
BR112018072714A2 (pt) composições de ligação a hcl para e método de tratamento de distúrbios de ácido-base
RU2018123666A (ru) Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина
JP2017522288A5 (https=)
Kelly et al. TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia
JP2016513523A5 (https=)
CN105400214A (zh) 一种使用透明质酸交联明胶制备止血棉的方法
Ali et al. HORMONAL INDUCTION OF OVARIAN CYCLICITY AND CONCEPTION RATE IN POSTPARTUM ANESTRUS BUFFALOES.
CN107137700B (zh) 一种基于干细胞源外泌体的组合物及其在制备治疗心肌梗死的药物中的应用
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2017525704A5 (https=)
Schmidt et al. Remote ischemic conditioning: the cardiologist's perspective
JP2016534062A5 (https=)
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES